AnaptysBio
ANAB
Market cap $482M

15.85 USD

+0.82

5.46%

At close Jan 17, 4:00 PM EST

After hours

15.85

+0.00

0.00%

1 day

5.46%

5 days

11.70%

1 month

-0.88%

3 months

-54.95%

6 months

-54.00%

Year to date

18.64%

1 year

-31.86%

5 years

-0.19%

10 years

-6.76%

About: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Employees: 117

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,823 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

236% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 11

88% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 32

50% more capital invested

Capital invested by funds: $749M [Q2] → $1.13B (+$378M) [Q3]

18% more funds holding

Funds holding: 135 [Q2] → 159 (+24) [Q3]

1.96% more ownership

Funds ownership: 109.44% [Q2] → 111.4% (+1.96%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

23% less call options, than puts

Call options by funds: $28.5M | Put options by funds: $36.9M

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$20

26%

upside

Avg. target

$33

108%

upside

High target

$40

152%

upside

5 analyst ratings

3 positive

60%

2 neutral

40%

0 negative

0%

JP Morgan Anupam Rama 19% 1-year accuracy 11 / 59 met price target	127%upside $36	Overweight Maintained	19 Dec 2024
Truist Securities John Lee 0 / 0 met price target	26%upside $20	Hold Maintained	18 Dec 2024
Wells Fargo Derek Archila 44% 1-year accuracy 16 / 36 met price target	152%upside $40	Overweight Maintained	12 Dec 2024
Guggenheim Yatin Suneja 32% 1-year accuracy 7 / 22 met price target	127%upside $36	Buy Maintained	12 Dec 2024
UBS Eliana Merle 16% 1-year accuracy 3 / 19 met price target	108%upside $33	Neutral Maintained	30 Oct 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry

AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025 at 4:30pm PT / 7:30pm ET.

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Zacks Investment Research

AnaptysBio Stock Down as Eczema Study Fails to Meet Goals

Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.

AnaptysBio Stock Down as Eczema Study Fails to Meet Goals

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

On Wednesday, AnaptysBio, Inc. ANAB announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema.

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

AnaptysBio to abandon eczema drug development after mid-stage trial failure

AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 40% lower.

AnaptysBio to abandon eczema drug development after mid-stage trial failure

AnaptysBio abandons eczema drug development after mid-stage trial failure

AnaptysBio said on Wednesday that it would discontinue the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial.

AnaptysBio abandons eczema drug development after mid-stage trial failure

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema. ANB032 was well tolerated with no safety signals observed.

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Zacks Investment Research

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Here is how AnaptysBio, Inc. (ANAB) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Zacks Investment Research

AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock?

AnaptysBio (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research

Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB)

The heavy selling pressure might have exhausted for AnaptysBio (ANAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB)

See News Rankings

Charts implemented using Lightweight Charts™